AMRI AMRI announced
today that it has signed an exclusive license agreement with Chai
Therapeutics, LLC for the development of ALB 109564(a), AMRI's novel tubulin
inhibitor compound in late Phase I testing for the treatment of cancer. This
agreement follows the exercise of an option to license the intellectual
property, which was granted in March 2012 by AMRI to Bessor Pharma, LLC, a
translational drug development company. Chai Therapeutics is an affiliate of
Bessor Pharma, LLC.
Under the terms of the license agreement, AMRI received an undisclosed license
fee and reimbursement for certain costs associated with the intellectual
property related to ALB 109564(a). Chai Therapeutics received an exclusive
license to the ALB 109564(a) intellectual property, and will be solely
responsible for all related research and development and patent costs going
forward; AMRI will receive a share of future consideration from the further
development and sales, if any, of any ALB 109564(a)-related drug that may be
developed, licensed and/or commercialized.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in